iBio (NYSEAMERICAN:IBIO) Stock Price Crosses Above 50 Day Moving Average of $0.00

iBio, Inc. (NYSEAMERICAN:IBIOGet Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $0.31. iBio shares last traded at $0.30, with a volume of 1,593,115 shares trading hands.

Several equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of iBio from a “sell” rating to a “hold” rating in a research report on Tuesday, April 19th. JMP Securities reiterated a “buy” rating and set a $1.50 price target on shares of iBio in a research report on Tuesday, February 15th.

The company has a debt-to-equity ratio of 0.24, a quick ratio of 7.85 and a current ratio of 8.09. The company has a market cap of $63.86 million, a price-to-earnings ratio of -2.25 and a beta of -5.36.

iBio (NYSEAMERICAN:IBIOGet Rating) last announced its quarterly earnings results on Monday, February 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. iBio had a negative net margin of 1,737.25% and a negative return on equity of 38.17%. The company had revenue of $0.17 million during the quarter. As a group, equities analysts predict that iBio, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of iBio by 14.8% in the third quarter. Geode Capital Management LLC now owns 4,100,969 shares of the biotechnology company’s stock valued at $4,347,000 after purchasing an additional 528,284 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of iBio by 19.1% in the third quarter. Bank of New York Mellon Corp now owns 727,537 shares of the biotechnology company’s stock valued at $771,000 after purchasing an additional 116,698 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of iBio by 55.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 365,389 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 129,809 shares during the last quarter. Barclays PLC increased its holdings in shares of iBio by 197.0% in the fourth quarter. Barclays PLC now owns 262,314 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 173,996 shares during the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of iBio in the fourth quarter valued at $120,000. Institutional investors and hedge funds own 20.54% of the company’s stock.

About iBio (NYSEAMERICAN:IBIO)

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.

See Also

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.